Heron Therapeutics (HRTX) Tops Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Heron Therapeutics (HRTX) Tops Q3 EPS by 10c

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates

November 3, 2021 4:01 PM EDT

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and nine months ended September 30, 2021 and highlighted recent corporate updates.

Recent Corporate Updates

Acute Care Franchise

ZYNRELEF Now Available: The ZYNRELEF (bupivacaine and meloxicam) extended-release solution New Drug Application (NDA) was... More